BICYCLE THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.18 USD | -0.81% |
|
-5.94% | +22.68% |
Presenter SpeechPeter Lawson (Analysts)Thank you so much, and good morning. Welcome to Barclay...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
22.18
USD
Average target price
44
USD
Spread / Average Target
+98.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.68% | 946M | |
| +8.29% | 114B | |
| +10.21% | 104B | |
| +0.41% | 22.28B | |
| -11.90% | 22.41B | |
| -5.99% | 19.07B | |
| -37.36% | 18B | |
| -5.17% | 17.89B | |
| +7.70% | 14.28B | |
| +37.65% | 12.55B |
- Stock Market
- Equities
- BCYC Stock
- News Bicycle Therapeutics plc
- Transcript : Bicycle Therapeutics plc Presents at Barclays Global Healthcare Conference, Mar-16-2023 09
